摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-[(pyridin-3-yl)(thien-2-yl)methyl]-3,5,6-trimethyl-1,4-benzoquinone

中文名称
——
中文别名
——
英文名称
2-[(pyridin-3-yl)(thien-2-yl)methyl]-3,5,6-trimethyl-1,4-benzoquinone
英文别名
2-[(3-pyridyl)(2-thienyl)methyl]-3,5,6-trimethyl-1,4-benzoquinone;2,3,5-trimethyl-6-[pyridin-3-yl(thiophen-2-yl)methyl]cyclohexa-2,5-diene-1,4-dione
2-[(pyridin-3-yl)(thien-2-yl)methyl]-3,5,6-trimethyl-1,4-benzoquinone化学式
CAS
——
化学式
C19H17NO2S
mdl
——
分子量
323.415
InChiKey
XFWCJFVQGOVPIS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    23
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.21
  • 拓扑面积:
    75.3
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-[(pyridin-3-yl)(thien-2-yl)methyl]-3,5,6-trimethyl-1,4-benzoquinone 生成 2,3,5-Trimethyl-6-[pyridin-3-yl(thiophen-2-yl)methyl]cyclohexa-2,5-diene-1,4-dione;hydrochloride
    参考文献:
    名称:
    TEHRAO, SINDZI;NISIKAVA, KOXEHJ
    摘要:
    DOI:
  • 作为产物:
    描述:
    1,1-二氯乙烷三甲基氢醌3-吡啶基(2-噻吩基)甲醇碳酸氢钠甲烷磺酸 作用下, 以6.0 g (92.3%)的产率得到2-[(pyridin-3-yl)(thien-2-yl)methyl]-3,5,6-trimethyl-1,4-benzoquinone
    参考文献:
    名称:
    Certain benzoquinones, naphthoquinones, corresponding hydroquinones
    摘要:
    喹醌衍生物由通式表示##STR1##(其中,R.sup.1和R.sup.2,相同或不同,指氢原子,甲基或甲氧基甲基基团,或R.sup.1和R.sup.2结合在一起形成--CH.dbd.CH--CH.dbd.CH--; R.sup.3是氢原子或甲基; R.sup.4是氮含杂环基团,可能被取代; R.sup.5是氢原子,甲基,可能被取代的羟甲基基团,或者酯化或酰胺化的羧基; Z是##STR2##(其中,R'是氢原子或甲基); n是0到12之间的整数,m是0到3之间的整数,k是0到7之间的整数,假设当m为2或3时,Z和k能够适当变化在[ ]中显示的重复单元中),以及其对氢醌衍生物,是新颖的化合物,具有改善多不饱和脂肪酸代谢的效果,特别是抑制脂肪酸过氧化物的产生,抑制5-脂氧合酶途径代谢产物的产生,抑制血栓素A.sub.2合成酶,血栓素A.sub.2受体拮抗作用和活性氧物质的清除作用,以及作为药物的用途,如抗血栓药、抗血管收缩剂、抗哮喘药、抗过敏药、治疗银屑病、改善心脏、脑和心血管系统的药物、治疗肾炎、活性氧清除剂、抗癌药、改善阿拉基酸级联产物控制的药物等。
    公开号:
    US04851413A1
点击查看最新优质反应信息

文献信息

  • Certain benzoquinones, naphthoquinones, corresponding hydroquinones
    申请人:Takeda Chemical Industries, Ltd.
    公开号:US04851413A1
    公开(公告)日:1989-07-25
    Quinone derivatives represented by the general formula ##STR1## (wherein, R.sup.1 and R.sup.2, the same or different, refer to a hydrogen atom, methyl or methoxymethyl group, or R.sup.1 and R.sup.2 bind together to form --CH.dbd.CH--CH.dbd.CH--; R.sup.3 is a hydrogen atom or methyl group; R.sup.4 is a nitrogen-containing heterocyclic group which may be substituted; R.sup.5 is a hydrogen atom, methyl group, hydroxymethyl group which may be substituted, or a carboxyl group which may be esterified or amidated; Z is ##STR2## (wherein, R' is hydrogen atom or methyl group); n is an integer from 0 through 12, m is an integer from 0 through 3, and k is an integer from 0 through 7, providing that, when m is 2 or 3, Z and k are able to vary appropriately in the repeating unit shown in [ ]), and the hydroquinone derivatives thereof, are novel compounds, possess improvement effects of metabolism of polyunsaturated fatty acids, particularly two or more of inhibition of production of fatty acid peroxides, inhibition of production of metabolites in 5-lipoxygenase pathway, inhibition of thromboxane A.sub.2 synthetase, thromboxane A.sub.2 receptor antagonism and scavenging action of active oxygen species, and of use as drugs, such as antithrombotics, anti-vascular constriction agents, anti-asthma agent, antiallergic agents, therapeutics for psoriasis, agents for improvement in heart, brain and cardiovascular systems, therapeutics for nephritis, active oxygen-eliminating agents, anticancer agents, agents for improvement of control of arachidonate cascade products, etc.
    喹醌衍生物由通式表示##STR1##(其中,R.sup.1和R.sup.2,相同或不同,指氢原子,甲基或甲氧基甲基基团,或R.sup.1和R.sup.2结合在一起形成--CH.dbd.CH--CH.dbd.CH--; R.sup.3是氢原子或甲基; R.sup.4是氮含杂环基团,可能被取代; R.sup.5是氢原子,甲基,可能被取代的羟甲基基团,或者酯化或酰胺化的羧基; Z是##STR2##(其中,R'是氢原子或甲基); n是0到12之间的整数,m是0到3之间的整数,k是0到7之间的整数,假设当m为2或3时,Z和k能够适当变化在[ ]中显示的重复单元中),以及其对氢醌衍生物,是新颖的化合物,具有改善多不饱和脂肪酸代谢的效果,特别是抑制脂肪酸过氧化物的产生,抑制5-脂氧合酶途径代谢产物的产生,抑制血栓素A.sub.2合成酶,血栓素A.sub.2受体拮抗作用和活性氧物质的清除作用,以及作为药物的用途,如抗血栓药、抗血管收缩剂、抗哮喘药、抗过敏药、治疗银屑病、改善心脏、脑和心血管系统的药物、治疗肾炎、活性氧清除剂、抗癌药、改善阿拉基酸级联产物控制的药物等。
  • Certain benzoquinones, naphthoquinones and derivatives thereof which
    申请人:Takeda Chemical Industries, Ltd.
    公开号:US04985447A1
    公开(公告)日:1991-01-15
    Quinone derivatives represented by the general formula ##STR1## (wherein, R.sup.1 and R.sup.2, the same or different, refer to hydrogen atom, methyl or methoxymethyl group, or R.sup.1 and R.sup.2 bind together to form --CH.dbd.CH--CH.dbd.CH--; R.sup.3 is hydrogen atom or methyl group; R.sup.4 is nitrogen-containing heterocyclic group which may be substituted; R.sup.5 is hydrogen atom, methyl group, hydroxymethyl group which may be substituted, or carboxyl group which may be esterified or amidated; Z is ##STR2## --CH.dbd.CH--, ##STR3## or ##STR4## (wherein, R' is hydrogen atom or methyl group); n is an integer from 0 through 12, m is an integer from 0 through 3, and k is an integer from 0 through 7, providing that, when m is 2 or 3, Z and k are able to vary appropriately in the repeating unit shown in [ ]), and the hydroquinone derivatives thereof, are novel compounds, possess improvement effects of metabolism of poly unsaturated fatty acids, particularly two or more inhibitition of production of fatty acid peroxides, inhibition of production of metabolites in 5-lipoxygenase pathway, inhibition of thromboxane A.sub.2 synthetase, thromboxane A.sub.2 receptor antagonism and scavenging action of active oxygen species, and of use as drugs, such as antithrombotics, anti-vascular constriction agents, anti-asthma agent, antiallergic agents, therpeutics for psoriasis, agents for improvement in heart, brain and cardiovascular systems, therapeutics for nephritis, active oxygen-eliminating agents, anticancer agents, agents for improvement of control of arachidonate cascade products, etc.
    通式为##STR1##的醌衍生物(其中,R.sup.1和R.sup.2,相同或不同,指氢原子,甲基或甲氧甲基基团,或R.sup.1和R.sup.2结合形成--CH.dbd.CH--CH.dbd.CH--; R.sup.3是氢原子或甲基基团; R.sup.4是可能被取代的含氮杂环基团; R.sup.5是氢原子,甲基基团,可能被取代的羟甲基基团,或可酯化或酰胺化的羧基; Z是##STR2## --CH.dbd.CH--, ##STR3## 或 ##STR4##(其中,R'是氢原子或甲基基团); n是0到12的整数,m是0到3的整数,k是0到7的整数,但当m为2或3时,Z和k能够在[ ]中所示的重复单位中适当变化),以及其羟醌衍生物,是新颖的化合物,具有改善多不饱和脂肪酸代谢的效果,特别是抑制脂肪酸过氧化物的产生,抑制5-脂氧合酶途径代谢物的产生,抑制血栓素A.sub.2合酶,血栓素A.sub.2受体拮抗作用和活性氧自由基清除作用,并可用作药物,如抗血栓剂,抗血管收缩剂,抗哮喘剂,抗过敏剂,治疗银屑病的药物,改善心脏,脑和心血管系统的药物,治疗肾炎的药物,活性氧清除剂,抗癌剂,改善花生四烯酸级联产物控制的药物等。
  • TEHRAO, SINDZI;NISIKAVA, KOXEHJ
    作者:TEHRAO, SINDZI、NISIKAVA, KOXEHJ
    DOI:——
    日期:——
  • TERAO, SHINJI;NISHIKAWA, KOHEI
    作者:TERAO, SHINJI、NISHIKAWA, KOHEI
    DOI:——
    日期:——
  • US4851413A
    申请人:——
    公开号:US4851413A
    公开(公告)日:1989-07-25
查看更多

同类化合物

(5β,6α,8α,10α,13α)-6-羟基-15-氧代黄-9(11),16-二烯-18-油酸 (3S,3aR,8aR)-3,8a-二羟基-5-异丙基-3,8-二甲基-2,3,3a,4,5,8a-六氢-1H-天青-6-酮 (2Z)-2-(羟甲基)丁-2-烯酸乙酯 (2S,4aR,6aR,7R,9S,10aS,10bR)-甲基9-(苯甲酰氧基)-2-(呋喃-3-基)-十二烷基-6a,10b-二甲基-4,10-dioxo-1H-苯并[f]异亚甲基-7-羧酸盐 (+)顺式,反式-脱落酸-d6 龙舌兰皂苷乙酯 龙脑香醇酮 龙脑烯醛 龙脑7-O-[Β-D-呋喃芹菜糖基-(1→6)]-Β-D-吡喃葡萄糖苷 龙牙楤木皂甙VII 龙吉甙元 齿孔醇 齐墩果醛 齐墩果酸苄酯 齐墩果酸甲酯 齐墩果酸乙酯 齐墩果酸3-O-alpha-L-吡喃鼠李糖基(1-3)-beta-D-吡喃木糖基(1-3)-alpha-L-吡喃鼠李糖基(1-2)-alpha-L-阿拉伯糖吡喃糖苷 齐墩果酸 beta-D-葡萄糖酯 齐墩果酸 beta-D-吡喃葡萄糖基酯 齐墩果酸 3-乙酸酯 齐墩果酸 3-O-beta-D-葡吡喃糖基 (1→2)-alpha-L-吡喃阿拉伯糖苷 齐墩果酸 齐墩果-12-烯-3b,6b-二醇 齐墩果-12-烯-3,24-二醇 齐墩果-12-烯-3,21,23-三醇,(3b,4b,21a)-(9CI) 齐墩果-12-烯-3,11-二酮 齐墩果-12-烯-2α,3β,28-三醇 齐墩果-12-烯-29-酸,3,22-二羟基-11-羰基-,g-内酯,(3b,20b,22b)- 齐墩果-12-烯-28-酸,3-[(6-脱氧-4-O-b-D-吡喃木糖基-a-L-吡喃鼠李糖基)氧代]-,(3b)-(9CI) 鼠特灵 鼠尾草酸醌 鼠尾草酸 鼠尾草酚酮 鼠尾草苦内脂 黑蚁素 黑蔓醇酯B 黑蔓醇酯A 黑蔓酮酯D 黑海常春藤皂苷A1 黑檀醇 黑果茜草萜 B 黑五味子酸 黏黴酮 黏帚霉酸 黄黄质 黄钟花醌 黄质醛 黄褐毛忍冬皂苷A 黄蝉花素 黄蝉花定